ClinicalTrials.Veeva
Menu

Find clinical trials for Non-Small-Cell Lung Cancer in Indianapolis, IN

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Non-Small-Cell Lung Carcinoma
Lung Cancer
Colorectal Cancer
Cancer
Squamous Cell Carcinoma of Head and Neck
Neoplasm Metastasis
Melanoma

Non-Small-Cell Lung Cancer trials near Indianapolis, IN, USA:

A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-small cell...

Enrolling
Non Small Cell Lung Cancer
Drug: Docetaxel
Biological: Telisotuzumab Vedotin

Phase 3

AbbVie
AbbVie

Indianapolis, Indiana, United States and 322 other locations

A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer. (eVOLVE-Lung02)

The purpose of eVOLVE-Lung02 is to test the effectiveness (efficacy) and measure the safety of volrustomig in combination with chemotherapy ...

Active, not recruiting
Metastatic Non-small Cell Lung Cancer
Drug: Pembrolizumab
Drug: Pemetrexed

Phase 3

AstraZeneca
AstraZeneca

Indianapolis, Indiana, United States and 246 other locations

Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-12)

This Phase 3 study will evaluate the efficacy of the investigational agent MRTX849 (adagrasib) versus docetaxel in patients who have been previously...

Active, not recruiting
Advanced Non Small Cell Lung Cancer
Metastatic Non Small Cell Lung Cancer
Drug: Docetaxel
Drug: MRTX849

Phase 3

Mirati Therapeutics
Mirati Therapeutics

Indianapolis, Indiana, United States and 389 other locations

Locations recently updated

Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

(pembrolizumab with chemotherapy) for adults with a type of lung cancer called non-small cell lung...

Enrolling
Carcinoma, Non-Small-Cell Lung (NSCLC)
Lung Cancer
Biological: Pembrolizumab
Biological: PF-08634404

Phase 3

Pfizer
Pfizer

Indianapolis, Indiana, United States and 477 other locations

Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)

in previously untreated patients with locally advanced or metastatic non-squamous Non-Small Cell Lung Ca...

Active, not recruiting
Metastatic Non-Small Cell Lung Cancer
Advanced Non-Small Cell Lung Cancer
Drug: platinum-based chemotherapy
Drug: furmonertinib 240 mg oral, daily

Phase 3

ArriVent BioPharma
ArriVent BioPharma

Indianapolis, Indiana, United States and 207 other locations

A Study of Tolododekin Alfa (ANK-101) in Combination With an Anti-PD-1/PD-L1 Antibody in Participants With Advanced Non-Small Cell Lung Cancer

A study of tolododekin alfa (also known as ANK-101) administered in combination with an anti-programmed cell death protein 1 (PD-1)/programm-...

Enrolling
Non Small Cell Lung Cancer
Drug: tolododekin alfa
Drug: Cetrelimab

Phase 1

Ankyra Therapeutics

Indianapolis, Indiana, United States and 10 other locations

Evaluating a Fasting-mimicking Diet in Combination With Immunotherapy in Patients With Non-small Cell Lung Cancer (Stage IV NSCLC)

The purpose of this study is to learn the effects of fasting on cancer cells while you get maintenance treatment....

Enrolling
Immunotherapy
Stage IV NSCLC
Dietary Supplement: FMD
Combination Product: Regular Diet Plus FMD
VA Office of Research and Development
VA Office of Research and Development

Indianapolis, Indiana, United States and 3 other locations

Adjuvant Pembrolizumab vs Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm

observation following surgical resection in patients with stage I non-small cell lung cancer (NSCLC) wit...

Enrolling
NSCLC, Stage I
Drug: Pembrolizumab

Phase 2

Greg Durm, MD

Indianapolis, Indiana, United States and 12 other locations

Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study

versus standard of care chemotherapy for the treatment of non-small cell lung cancer that is stage IV or...

Active, not recruiting
Recurrent Lung Non-Small Cell Carcinoma
Stage IV Lung Cancer AJCC v8
Biological: Pembrolizumab
Biological: Ramucirumab

Phase 3

SWOG Cancer Research Network
SWOG Cancer Research Network

Indianapolis, Indiana, United States and 566 other locations

Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)

This phase II/III Expanded Lung-MAP treatment trial compares the effect of adding cemiplimab to docetaxel and ramucirumab versus docetaxel a-...

Enrolling
Recurrent Lung Non-Small Cell Carcinoma
Stage IV Lung Cancer AJCC v8
Drug: Docetaxel
Procedure: Biospecimen Collection

Phase 2, Phase 3

SWOG Cancer Research Network
SWOG Cancer Research Network

Indianapolis, Indiana, United States and 385 other locations

Clinical trials

Find clinical trialsTrials by location

Research sites

Find research sitesLearn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy NoticeTerms
© Copyright 2026 Veeva Systems